Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 4 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 4 25 IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER vs DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Delflex with 4.25% dextrose is a peritoneal dialysis solution that removes waste products, electrolytes, and excess fluid from the blood via diffusion and ultrafiltration across the peritoneal membrane. Dextrose creates an osmotic gradient, drawing fluid and solutes from the capillaries into the peritoneal cavity.
Intraperitoneal administration of hypertonic dextrose solution creates an osmotic gradient across the peritoneal membrane, facilitating ultrafiltration and removal of uremic toxins through peritoneal dialysis.
Continuous ambulatory peritoneal dialysis (CAPD)Continuous cycling peritoneal dialysis (CCPD)Automated peritoneal dialysis (APD)Management of end-stage renal disease (ESRD)
Continuous ambulatory peritoneal dialysis (CAPD) for end-stage renal diseaseContinuous cyclic peritoneal dialysis (CCPD)Off-label: Acute kidney injury requiring peritoneal dialysisOff-label: Management of severe fluid overload unresponsive to diuretics
Intraperitoneal administration: 2 to 2.5 liters per exchange, 4 to 5 exchanges per day, as part of continuous ambulatory peritoneal dialysis (CAPD).
Intraperitoneal administration: 2 liters per exchange, 4 exchanges per day, or as prescribed for continuous ambulatory peritoneal dialysis (CAPD); may adjust volume and frequency based on patient's fluid and electrolyte status.
None Documented
None Documented
Not applicable as a combination solution; glucose half-life ~1.5-2 hours in normal renal function; prolonged in renal impairment.
Dextrose terminal half-life is approximately 1-2 hours in normal metabolism; in peritoneal dialysis, continuous removal leads to variable half-life depending on dwell time and ultrafiltration; clinical context: continuous exposure during dwell.
Dextrose is absorbed systemically and metabolized via glycolysis and the Krebs cycle. No hepatic metabolism for the solution components; waste removal is achieved through peritoneal dialysis. Insulin may be required to manage hyperglycemia.
Dextrose undergoes rapid cellular uptake and metabolism via glycolysis and subsequent oxidative phosphorylation; minimal hepatic metabolism.
Renal: >90% as unchanged glucose and electrolytes; negligible biliary/fecal elimination.
Peritoneal dialysis solution; dextrose is metabolized and eliminated via peritoneal dialysis; approximately 70-80% of dextrose is absorbed systemically and metabolized; the non-absorbed fraction is removed with dialysate outflow; lactate (buffer) is converted to bicarbonate in the liver and eliminated via respiration and urine.
Minimal (<10%); glucose and electrolytes do not significantly bind to plasma proteins.
Dextrose: negligible (<1%); not bound to proteins.
Glucose: ~0.2 L/kg (extracellular fluid); electrolytes distribute according to body water compartments.
Dextrose: Vd 0.2-0.4 L/kg (total body water); distributes throughout extracellular and intracellular fluid.
Intraperitoneal: ~70-80% for glucose absorption; electrolytes 100% bioavailable via peritoneal route.
Intraperitoneal: 100% (directly into peritoneal cavity); systemic absorption of dextrose occurs via peritoneal capillaries (70-80% absorbed over dwell).
Not applicable; drug is used for renal replacement therapy in end-stage renal disease.
No dose adjustment required for renal impairment; however, monitor serum electrolytes and fluid balance closely in patients with residual renal function.
No specific adjustments; monitor for metabolic acidosis and electrolyte imbalances in severe hepatic impairment.
No specific dose adjustment recommended; use with caution in severe hepatic impairment due to risk of electrolyte disturbances and fluid overload.
Weight-based: 30 to 40 mL/kg per exchange, 4 to 5 exchanges per day; adjust based on residual renal function and ultrafiltration needs.
Individualized based on weight, body surface area, and peritoneal dialysis prescription; typical exchange volume: 30-40 mL/kg per exchange, 4-5 exchanges per day for CAPD; adjust dextrose concentration based on ultrafiltration needs.
No specific dose adjustments; monitor glucose and electrolyte levels closely due to higher risk of hyperglycemia and fluid overload.
No specific dose adjustment; monitor for fluid overload and electrolyte imbalances, adjust dextrose concentration and exchange volume as needed, consider reduced volume and frequency in patients with compromised cardiac or renal function.
Peritoneal dialysis solutions with dextrose, including Delflex with 4.25% dextrose, are contraindicated in patients with pre-existing severe hyperglycemia or who are hypersensitive to any component of the product. The solution is for peritoneal administration only, not for intravenous use. Strict sterile technique in catheter placement and fluid exchange is required to prevent peritonitis.
None.
["Hyperglycemia and hyperosmolar syndrome, especially in patients with diabetes mellitus","Peritonitis and exit-site infections; strict aseptic technique required","Electrolyte imbalances (hypokalemia, hypomagnesemia, hypocalcemia) due to low magnesium and low calcium formulation","Protein loss and malnutrition","Fluid overload or dehydration (monitor fluid balance)","Hernias and abdominal discomfort","Peritoneal catheter complications"]
["Peritonitis: Use strict aseptic technique; monitor for signs of infection","Mechanical complications: Catheter malfunction, leakage, hernia","Metabolic disturbances: Hyperglycemia, hyperosmolarity, electrolyte imbalances","Hypersensitivity: Rare allergic reactions to components","Volume overload: Monitor ultrafiltration and body weight"]
["Hypersensitivity to any component","Pre-existing severe hyperglycemia or uncontrolled diabetes","Peritoneal adhesions, fibrosis, or sclerosis","Abdominal wall infection or peritonitis","Recent abdominal surgery or trauma","Severe pulmonary disease (risk of respiratory compromise)","Collagen vascular disease (e.g., scleroderma)","Uncorrectable mechanical defects (e.g., catheter malfunction)"]
["Pre-existing severe hyperglycemia","Hypersensitivity to dextrose or any component","Clinically significant peritoneal membrane abnormalities (e.g., extensive adhesions, recent surgery)","Severe respiratory acidosis (relative contraindication)"]
Data Pending Review
Data Pending Review
No direct food interactions, but patients on peritoneal dialysis may require dietary restrictions for potassium, phosphorus, and sodium. Avoid excessive intake of calcium- or magnesium-rich foods (e.g., dairy, nuts, leafy greens) if monitoring indicates imbalances. Dextrose absorption may affect blood glucose; manage carbohydrate intake accordingly.
No direct food interactions with Delflex-LM w/ Dextrose 4.25% as it is intraperitoneal. However, dietary restrictions for renal failure apply: limit sodium, potassium, phosphorus, and fluid intake. Dextrose absorption may affect blood glucose; diabetic patients should adjust diet and insulin accordingly.
Delflex w/ Dextrose 4.25% Low Magnesium Low Calcium is a peritoneal dialysis solution. There are no adequate studies in pregnant women. Peritoneal dialysis itself may pose risks (e.g., infection, preterm labor). Dextrose may cause maternal hyperglycemia and fetal hyperinsulinism. Use only if clearly needed, weighing risks vs benefits. Trimester-specific risks are not established; reports of congenital anomalies are not directly attributed to the solution.
Insufficient human data; animal studies not available. Icodextrin and dextrose are not known teratogens, but risks cannot be excluded. In first trimester, theoretical risk of metabolic disturbance; second and third trimesters, possible volume overload. Use only if clearly needed.
It is unknown whether Delflex components are excreted in human milk. Dextrose and electrolytes are endogenous substances. The M/P ratio is not available. Caution is advised; consider risk of infant exposure to small amounts of dialysate components.
Unknown if icodextrin or dextrose metabolites excreted in human milk. M/P ratio not established. Caution in breastfeeding women; consider benefits vs risks.
No specific dose adjustment recommendations during pregnancy. Pharmacokinetic changes (e.g., increased volume of distribution, altered electrolyte needs) may require careful monitoring and adjustment of exchange volume, frequency, and electrolyte composition to maintain metabolic control. Consult nephrology for individualized therapy.
No specific dose adjustments established; pharmacokinetic changes in pregnancy (increased plasma volume, renal function) may affect drug clearance. Monitor adequacy of dialysis and adjust exchange volume/frequency as needed to maintain target solute clearance and ultrafiltration.
Category C
Category C
This solution is used in peritoneal dialysis. The low magnesium and low calcium formulation is indicated for patients with hypermagnesemia or hypercalcemia, or to adjust electrolyte balance. Monitor serum magnesium and calcium levels regularly. The 4.25% dextrose concentration provides higher ultrafiltration; use with caution in patients with hyperglycemia or insulin-dependent diabetes. Check for solution cloudiness or leaks before use. Warm solution to body temperature before infusion to reduce discomfort.
Delflex-LM w/ Dextrose 4.25% is a peritoneal dialysis solution. Verify solution clarity and integrity before use. Warm solution to body temperature to minimize discomfort. Use aseptic technique for all connections to reduce peritonitis risk. Monitor effluent for clarity; cloudy effluent may indicate infection. Check blood glucose levels closely in diabetic patients due to dextrose absorption. Adequacy of dialysis should be assessed by Kt/V and creatinine clearance. Do not administer intravenously.
Follow strict sterile technique during bag exchange to prevent peritonitis.Check the solution for clarity, color, and leaks before use.Warm the solution to body temperature before infusion for comfort.Monitor for signs of infection (abdominal pain, fever, cloudy effluent) and report immediately.Keep a log of your weight, blood pressure, and inflow/outflow volumes.Do not modify the solution composition without consulting your healthcare provider.
Store solution at room temperature, avoid extreme heat or cold.Check solution bag for leaks, cloudiness, or discoloration before use; do not use if compromised.Warm the solution to body temperature (use dry heat, not microwave) before infusion.Perform exchange in a clean, well-lit area and wash hands thoroughly.Use sterile technique when connecting and disconnecting lines.Monitor your weight and blood pressure daily and report changes.Report any signs of peritonitis: cloudy effluent, abdominal pain, fever, nausea, or vomiting.Follow a renal diet as advised by your dietitian, including fluid, sodium, potassium, and phosphorus restrictions.Do not reuse solution or administration sets.Contact healthcare provider if you experience shortness of breath or swelling (signs of fluid overload).